Bleomycin for Injection USP 15 Unit (Bleomycin (Bleomycin Sulfate) POWDER FOR SOLUTION) 15 UNIT

Bleomycin for Injection USP 15 Unit is a powder for solution used in various medical treatments. This medication, manufactured by Pfizer Canada ULC, is administered intra-arterially for specific therapeutic purposes.

Strength

15 UNIT

Pack Size

10ML VIAL

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bleomycin for Injection USP 15 Unit is primarily used in the treatment of certain types of cancer. It works by interfering with the growth of cancer cells, making it a valuable option for what is Bleomycin used for in oncology. This medication is often part of a broader treatment plan tailored to individual patient needs.

Side Effects

Common effects of Bleomycin for Injection USP 15 Unit may include skin reactions, fever, and changes in lung function. These effects can vary widely among individuals and should be monitored by a healthcare professional. Always follow medical advice regarding the administration and monitoring of this medication.

Precautions & Warnings

Bleomycin for Injection USP 15 Unit should be handled with care to avoid contamination. It is important to follow proper storage and administration guidelines to ensure safety. Patients should be aware of potential side effects and report any unusual symptoms to their healthcare provider immediately.

Avoid Interactions

Bleomycin for Injection USP 15 Unit may interact with other medications, including those that affect the immune system or lung function. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always consult a medical professional before starting any new treatment.

Frequently Asked Questions

Bleomycin for Injection USP 15 Unit is used in the treatment of certain types of cancer, often as part of a broader treatment plan.

This medication is administered intra-arterially, meaning it is injected directly into an artery.

Common side effects may include skin reactions, fever, and changes in lung function.

Bleomycin for Injection USP 15 Unit is manufactured by Pfizer Canada ULC.

Precautions include proper handling to avoid contamination and monitoring for potential side effects.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.